Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional vs. fractional CO2 laser-assisted photodynamic therapy for actinic keratoses and nodular basal cell carcinomas
2010-020179-22Phase 3Completed
- Sponsor
- Department of Dermatology
- Start
- May 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of methyl aminolevulinate in actinic keratosis (AK) and basal cell carcinoma (BCC) (2 arms), sponsored by Department of Dermatology. Primary endpoint: Reduction in number of treated actinic keratoses and nodular basal cell carcinomas. Started May 2010; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2010-020179-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020179-22.